CoreC The proposed Duke CFAR Flow Cytometry Core Facility will a) provide state-of-the-art, multi-color, BSL-3 fluorescence activated cell sorting support for basic research or translational investigations conducted by Duke CFAR members, including sorting HIV-1 infected cells, b) provide state-of-the-art, multi-color, BSL-2* flow cytometric analytical support for basic, translational, and clinical research investigations conducted by Duke CFAR members, and c) enhance the scientific approach used by Duke CFAR Investigators by educating the Core User base in more effective ways of utilizing the state-of-the-art tools offered by the Duke CFAR Flow Cytometry Core Facility, as well as to provide programmatic advancement for Managers and Operators of the CFAR Flow Cytometry Core Facility. The BSL-3 Sorting Component Laboratory will house the only flow cytometer at Duke University Medical Center capable of sorting live, unfixed human or animal derived cells, infected with HIV-1 or equivalent pathogens, and will prove an invaluable asset to the overall scope of the proposed Duke CFAR Flow Cytometry Core Facility. The Duke CFAR Flow Cytometry Core will be the only flow cytometry facility at Duke capable of providing polychromatic and flow informatic support for HIV and HIV-related translational research at Duke. The proposed Duke CFAR Flow Cytometry Core Facility will be comprised of two Component Laboratories, both housed in biocontainment laboratories within the SORF &Global Health Buildings, respectively. The Component Laboratories will be closely linked physically, administratively, and scientifically, in order to form a highly interactive and unified Duke CFAR Flow Cytometry Core Facility. The BSL-2* Analytical Component Laboratory will provide a broad range of polychromatic flow cytometry applications to CFAR investigators and, together with the BSL-3 Sorting Component Laboratory, comprise the only flow cytometry research facility on campus that routinely processes, sorts, and analyzes HIV-1 infected specimens.
This Core makes state of the art immune monitoring technologies available to Duke scientists at the forefront of AIDS research. These tools will greatly facilitate rapid progress in the development of novel AIDS therapies and preventative AIDS vaccines.
|Zhang, Helen L; Rhea, Sarah K; Hurt, Christopher B et al. (2018) HIV Preexposure Prophylaxis Implementation at Local Health Departments: A Statewide Assessment of Activities and Barriers. J Acquir Immune Defic Syndr 77:72-77|
|Cichowitz, Cody; Mazuguni, Festo; Minja, Linda et al. (2018) Vulnerable at Each Step in the PMTCT Care Cascade: High Loss to Follow Up During Pregnancy and the Postpartum Period in Tanzania. AIDS Behav :|
|Tabb, Zachary J; Mmbaga, Blandina T; Gandhi, Monica et al. (2018) Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. AIDS 32:1115-1123|
|Williams, Wilton B; Han, Qifeng; Haynes, Barton F (2018) Cross-reactivity of HIV vaccine responses and the microbiome. Curr Opin HIV AIDS 13:9-14|
|Cherenack, Emily M; Sikkema, Kathleen J; Watt, Melissa H et al. (2018) Avoidant Coping Mediates the Relationship Between Self-Efficacy for HIV Disclosure and Depression Symptoms Among Men Who Have Sex with Men Newly Diagnosed with HIV. AIDS Behav 22:3130-3140|
|Sikkema, Kathleen J; Mulawa, Marta I; Robertson, Corne et al. (2018) Improving AIDS Care After Trauma (ImpACT): Pilot Outcomes of a Coping intervention Among HIV-Infected Women with Sexual Trauma in South Africa. AIDS Behav 22:1039-1052|
|Blasi, Maria; Negri, Donatella; LaBranche, Celia et al. (2018) IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Commun Biol 1:134|
|Collins, Lauren F; Chan, Austin; Zheng, Jiayin et al. (2018) Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection. Open Forum Infect Dis 5:ofx264|
|Wills, Saintedym; Hwang, Kwan-Ki; Liu, Pinghuang et al. (2018) HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. J Virol 92:|
|Watt, Melissa H; Knippler, Elizabeth T; Knettel, Brandon A et al. (2018) HIV Disclosure Among Pregnant Women Initiating ART in Cape Town, South Africa: Qualitative Perspectives During the Pregnancy and Postpartum Periods. AIDS Behav 22:3945-3956|
Showing the most recent 10 out of 488 publications